本页面由Tiger Trade Technology Pte. Ltd.提供服务

Vaxcyte, Inc.

70.65
-0.7300-1.02%
盘后:70.45-0.2000-0.28%19:30 EDT
成交量:242.77万
成交额:1.71亿
市值:110.37亿
市盈率:-9.24
高:72.89
开:71.08
低:68.97
收:71.38
52周最高:90.75
52周最低:39.87
股本:1.56亿
流通股本:1.48亿
量比:0.27
换手率:1.64%
股息:- -
股息率:- -
每股收益(TTM):-7.6496
每股收益(LYR):-5.6333
净资产收益率:-36.51%
总资产收益率:-22.61%
市净率:4.00
市盈率(LYR):-12.54

数据加载中...

2026/10/09

重要事件披露

Form 8-K - Current report
2026/10/07

[补充]招股说明书

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2026/10/05

关联方拟减持公告

Form 144 | Vaxcyte, Inc. 高管 Cowan Elvia 拟减持19000股普通股,总市值约164.81万美元
2026/10/05

关联方拟减持公告

Form 144 | Vaxcyte, Inc. 高管 James Wassil 拟减持18000股普通股,合计约156.13万美元
2026/10/05

重要事件披露

Form 8-K - Current report
2026/10/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/03

重要事件披露

Form 8-K - Current report
2026/09/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/11

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/07

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/06

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/05

重要事件披露

Form 8-K - Current report
2026/08/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/07/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/07/15

重要事件披露

Form 8-K - Current report